Cliff Asness's NEO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 146,352 shares of NeoGenomics, Inc. (NEO) worth $1.72 M, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in NEO, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 141,187 shares. Largest reduction occurred in Q3 2025, reducing 103,714 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's NeoGenomics (NEO) Holding Value Over Time
Track share changes against reported price movement
Quarterly NeoGenomics (NEO) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +80,348 | Add 121.73% | 146,352 | $11.76 |
| Q3 2025 | -103,714 | Reduce 61.11% | 66,004 | $7.72 |
| Q2 2025 | +141,187 | Add 494.85% | 169,718 | $7.31 |
| Q1 2025 | +28,531 | New Buy | 28,531 | $9.49 |
| Q2 2024 | -11,901 | Sold Out | 0 | $0.00 |
| Q1 2024 | -8,518 | Reduce 41.72% | 11,901 | $15.72 |
| Q4 2023 | +8 | Add 0.04% | 20,419 | $16.18 |
| Q3 2023 | +4,532 | Add 28.54% | 20,411 | $12.30 |
| Q2 2023 | +15,879 | New Buy | 15,879 | $16.07 |
| Q1 2023 | -15,529 | Sold Out | 0 | $0.00 |
| Q4 2022 | -21,147 | Reduce 57.66% | 15,529 | $9.24 |
| Q3 2022 | +17,536 | Add 91.62% | 36,676 | $8.62 |
| Q2 2022 | +7,042 | Add 58.21% | 19,140 | $8.15 |
| Q1 2022 | -1,562 | Reduce 11.43% | 12,098 | $12.15 |
| Q4 2021 | -1,517 | Reduce 10.00% | 13,660 | $34.11 |
| Q1 2021 | -27,274 | Reduce 64.25% | 15,177 | $48.23 |
| Q4 2020 | -32,395 | Reduce 43.28% | 42,451 | $53.85 |
| Q3 2020 | -33,594 | Reduce 30.98% | 74,846 | $36.89 |
| Q2 2020 | -32,151 | Reduce 22.87% | 108,440 | $30.98 |
| Q1 2020 | +46,270 | Add 49.06% | 140,591 | $27.61 |
| Q4 2019 | -66,971 | Reduce 41.52% | 94,321 | $29.25 |
| Q3 2019 | -63,487 | Reduce 28.24% | 161,292 | $19.12 |
| Q2 2019 | +70,829 | Add 46.01% | 224,779 | $21.94 |
| Q1 2019 | -8,109 | Reduce 5.00% | 153,950 | $20.46 |
| Q4 2018 | +134,418 | Add 486.30% | 162,059 | $12.61 |
| Q3 2018 | +14,949 | Add 117.78% | 27,641 | $15.34 |
| Q2 2018 | -9,172 | Reduce 41.95% | 12,692 | $13.08 |
| Q3 2017 | -7,088 | Reduce 24.48% | 21,864 | $11.11 |
| Q2 2017 | -129 | Reduce 0.44% | 28,952 | $8.95 |
| Q1 2017 | -12,779 | Reduce 30.53% | 29,081 | $7.87 |
| Q4 2016 | -141 | Reduce 0.34% | 41,860 | $8.58 |
| Q3 2016 | +7,575 | Add 22.00% | 42,001 | $8.21 |
| Q1 2016 | +941 | Add 2.81% | 34,426 | $6.74 |
| Q4 2015 | -20,785 | Reduce 38.30% | 33,485 | $7.88 |
| Q3 2015 | +7,729 | Add 16.61% | 54,270 | $5.73 |
| Q2 2015 | +12,541 | Add 36.89% | 46,541 | $5.41 |
| Q1 2015 | +10,700 | Add 45.92% | 34,000 | $4.68 |
| Q4 2014 | +13,100 | Add 128.43% | 23,300 | $4.16 |
| Q3 2014 | +10,200 | New Buy | 10,200 | $5.20 |
Cliff Asness's NeoGenomics Investment FAQs
Cliff Asness first purchased NeoGenomics, Inc. (NEO) in Q3 2014, acquiring 10,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held NeoGenomics, Inc. (NEO) for 44 quarters since Q3 2014.
Cliff Asness's largest addition to NeoGenomics, Inc. (NEO) was in Q2 2025, adding 169,718 shares worth $1.24 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 146,352 shares of NeoGenomics, Inc. (NEO), valued at approximately $1.72 M.
As of the Q4 2025 filing, NeoGenomics, Inc. (NEO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in NeoGenomics, Inc. (NEO) was 224,779 shares, as reported at the end of Q2 2019.